Novartis will use vital radioisotope in cancer treatment technologies
This long-exposure image makes it possible to see the glow of actinium-225 (Ac-225), an isotope that shows great promise for treating cancer. Image courtesy Brookhaven National Laboratory.
US-based radioisotope manufacturer Niowave has signed a long-term agreement with Swiss pharmaceutical company Novartis to supply actinium-225 (Ac-225) to support its cancer treatment technologies.
What we offer
Independent news and information for and about the global nuclear industry
For nuclear incidents, NucNet operates 24 hours a day, 7 days a week
Daily, weekly and monthly newsletters
Access to infographics for subscribers to use in their own editorial and marketing material
Exclusive analysis and special reports on key nuclear industry topics
Breaking news on social media
Access to the ‘NucNet Style Guide for Nuclear Reporters and Communicators’
Access to NucNet editorial database containing more than 18,000 news articles and features from January 1991
A reliable media and communications partner for the nuclear energy industry. Distribution of your industry news stories
Manage your own preferences
Get involved. Members can attend meetings and be part of NucNet’s policy and editorial decision-making